Thus, in phase I and II trials, a tumor-specific BCR-ABL derived peptide vaccine could be safely administered to patients with chronic phase CML and elicit BCR-ABL peptide-specific CD4 immunity. This evidence concerns the gene ABL1 and neoplasm.